OGN vs TECX · P/E 3.4, rev $6.40B vs $567.2M cap
Organon & Co (OGN) versus Tectonic Therapeutic, Inc. (TECX) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Tectonic Therapeutic, Inc. (TECX) is a biotechnology company listed on NASDAQ.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
TECX does not have a complete income-statement cache yet.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. TECX currently screens at market cap $567.2M.
Not investment advice. Open the OGN and TECX stock pages for the full models.
Not investment advice.